Reported Consolidated quarterly numbers for Sun Pharmaceutical Industries are:
Net Sales at Rs 7,585.25 crore in June 2020 down 9.42% from Rs. 8,374.36 crore in June 2019.
Quarterly Net Loss at Rs. 1,655.60 crore in June 2020 down 219.32% from Rs. 1,387.48 crore in June 2019.
EBITDA stands at Rs. 1,997.30 crore in June 2020 down 9.57% from Rs. 2,208.63 crore in June 2019.
Sun Pharma shares closed at 531.70 on July 31, 2020 (NSE) and has given 22.43% returns over the last 6 months and 24.59% over the last 12 months.
Sun Pharmaceutical Industries | Consolidated Quarterly Results | in Rs. Cr. |
|
| Jun'20 | Mar'20 | Jun'19 | Net Sales/Income from operations | 7,467.19 | 8,078.03 | 8,259.30 | Other Operating Income | 118.06 | 106.91 | 115.06 | Total Income From Operations | 7,585.25 | 8,184.94 | 8,374.36 | EXPENDITURE | Consumption of Raw Materials | 1,518.84 | 1,209.58 | 1,335.83 | Purchase of Traded Goods | 683.32 | 910.64 | 810.23 | Increase/Decrease in Stocks | -232.56 | 184.59 | 311.73 | Power & Fuel | -- | -- | -- | Employees Cost | 1,759.04 | 1,651.89 | 1,540.40 | Depreciation | 495.92 | 575.38 | 457.13 | Excise Duty | -- | -- | -- | Admin. And Selling Expenses | -- | -- | -- | R & D Expenses | -- | -- | -- | Provisions And Contingencies | -- | -- | -- | Exp. Capitalised | -- | -- | -- | Other Expenses | 2,013.10 | 2,865.23 | 2,380.56 | P/L Before Other Inc., Int., Excpt. Items & Tax | 1,347.59 | 787.63 | 1,538.48 | Other Income | 153.79 | 102.23 | 213.02 | P/L Before Int., Excpt. Items & Tax | 1,501.38 | 889.86 | 1,751.50 | Interest | 51.95 | 51.78 | 104.06 | P/L Before Exceptional Items & Tax | 1,449.43 | 838.08 | 1,647.44 | Exceptional Items | -3,633.33 | -260.64 | -- | P/L Before Tax | -2,183.90 | 577.44 | 1,647.44 | Tax | 245.91 | 83.09 | 146.06 | P/L After Tax from Ordinary Activities | -2,429.81 | 494.35 | 1,501.38 | Prior Year Adjustments | -- | -- | -- | Extra Ordinary Items | -- | -- | -- | Net Profit/(Loss) For the Period | -2,429.81 | 494.35 | 1,501.38 | Minority Interest | 770.63 | -- | -109.17 | Share Of P/L Of Associates | 3.58 | -1.59 | -4.73 | Net P/L After M.I & Associates | -1,655.60 | 492.76 | 1,387.48 | Equity Share Capital | 239.93 | 239.93 | 239.93 | Reserves Excluding Revaluation Reserves | -- | -- | -- | Equity Dividend Rate (%) | -- | -- | -- | EPS Before Extra Ordinary | Basic EPS | -6.90 | 1.67 | 5.78 | Diluted EPS | -6.90 | 1.67 | 5.78 | EPS After Extra Ordinary | Basic EPS | -6.90 | 1.67 | 5.78 | Diluted EPS | -6.90 | 1.67 | 5.78 | Public Share Holding | No Of Shares (Crores) | -- | -- | -- | Share Holding (%) | -- | -- | -- | Promoters and Promoter Group Shareholding | a) Pledged/Encumbered | - Number of shares (Crores) | -- | -- | -- | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | b) Non-encumbered | - Number of shares (Crores) | -- | -- | -- | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | Source : Dion Global Solutions Limited |
|